Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study

BACKGROUND. Ixabepilone is an effective chemotherapy in metastatic breast cancer that has been pretreated with anthracyclines and is resistant or refractory to taxanes. Adjuvant dose-dense (DD) chemotherapy is more effective than regimens administered every 3 weeks, especially in hormonal receptor (...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Clavarezza, Matteo, Bordonaro, Roberto, Daniele, Bruno, Ferrandina, Gabriella, Barni, Sandro, Turazza, Monica, Coati, Francesca, De Matteis, Andrea, De Placido, Sabino, Cognetti, Francesco, Olmeo, Nina Antonina, Carrozza, Francesco, Bruzzi, Paolo, Del Mastrol, Lucia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2013
Aiheet:
Clinical Trial Results
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755929/
https://ncbi.nlm.nih.gov/pubmed/23939283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0222
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia